Olix Pharmaceuticals Inc. (226950)
KRX SM KRX SM Primary Summary
Olix Pharmaceuticals Inc. (226950) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Olix Pharmaceuticals Inc. ever had a stock split?
Olix Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Dong-Ki Lee Ph.D. CEO | KRX SM Exchange | KR7226950004 ISIN |
| South Korea Country | 66 Employees | - Last Dividend | 3 Dec 2020 Last Split | - IPO Date |
Overview
OliX Pharmaceuticals, Inc. is a pioneering biotech company concentrating on the development of RNA interference (RNAi) therapeutics aimed at treating a wide range of diseases affecting the dermal, ophthalmic, and pulmonary systems. Founded in 2010, the company has established its headquarters in Suwon-si, South Korea. OliX Pharmaceuticals has forged significant collaboration agreements, including with Théa for the development of SiRNA therapeutics targeting ophthalmic diseases, and with PCI Biotech Holding ASA for research collaboration. These partnerships underline the company's commitment to leveraging its RNAi technology platform to address unmet medical needs.
Products and Services
- OLX101A for Skin Scar
OLX101A represents a cutting-edge therapeutic approach targeting the treatment of skin scars. By harnessing RNAi technology, this product aims to modulate the gene expression involved in the scarring process, offering a novel solution for patients seeking to minimize scar formation.
- OLX201A for Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive lung disease characterized by the thickening and scarring of lung tissue. OLX201A is being developed to target the molecular pathways involved in the development of fibrosis, potentially offering a new hope for patients suffering from this debilitating condition.
- OLX301 for Age-Related Macular Degeneration
OLX301 is designed to address Age-Related Macular Degeneration (AMD), a common eye condition leading to vision loss among people over 50. By targeting specific RNA sequences, OLX301 aims to halt or slow the progression of AMD, preserving vision and improving the quality of life for aging populations.
- OLX301D for Subretinal Fibrosis
A derivative of OLX301, OLX301D is tailored to combat subretinal fibrosis, a severe form of macular degeneration leading to vision loss. This therapeutic option explores the potential of RNAi technology to reduce or prevent fibrotic tissue formation beneath the retina, offering a groundbreaking approach to a currently unaddressable aspect of ophthalmic disease.
